Recurrent Ovarian Cancer
Oncology·MeSH: Ovarian Neoplasms
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
7 drugs in development·4 companies·3 clinical trials
Drug Pipeline by Phase
Phase 2(5)
Phase 1(1)
| Drug | Company |
|---|---|
| LDE225 | Novartis AG (NVS) |
Phase 4(1)
| Drug | Company |
|---|---|
| saruparib | ASTRAZENECA PLC (AZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Recurrent Ovarian Cancer?
BioSniper tracks 7 drugs in development for Recurrent Ovarian Cancer across 4 companies.
How many clinical trials target Recurrent Ovarian Cancer?
There are 3 clinical trials targeting Recurrent Ovarian Cancer tracked by BioSniper.
What is the prevalence of Recurrent Ovarian Cancer?
The estimated prevalence of Recurrent Ovarian Cancer is approximately 24.0 per 100,000 population.
Deep-dive into Recurrent Ovarian Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis